Want to see TSE:INNO full AI Analyst Report?
InnoCan Pharma (INNO) Ratios
InnoCan Pharma Ratios
TSE:INNO's free cash flow for Q2 2026 was $-475.26K. For the 2026 fiscal year, TSE:INNO's free cash flow was decreased by $-9.02K and operating cash flow was $-466.24K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Mar 25 | Mar 24 | Dec 22 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 7.70 | 4.09 | 2.68 | 9.41 | 3.51 |
| Quick Ratio | 6.09 | 2.61 | 1.99 | 7.86 | 3.37 |
| Cash Ratio | 4.94 | 2.24 | 1.53 | 6.77 | 3.10 |
| Solvency Ratio | -0.47 | -0.80 | -1.83 | -5.13 | -2.81 |
| Operating Cash Flow Ratio | 0.37 | -0.71 | -1.54 | -8.30 | -1.86 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 8.15M | $ 6.91M | $ 4.25M | $ 6.13M | $ 8.96M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.09 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.17 | 0.00 | 0.01 | 0.01 | 0.00 |
| Debt-to-Capital Ratio | 0.14 | 0.00 | 0.01 | 0.01 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.14 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.88 | 1.79 | 1.69 | 1.09 | 1.39 |
| Debt Service Coverage Ratio | -98.67 | -31.43 | 0.00 | -1926.00 | -769.54 |
| Interest Coverage Ratio | -418.33 | -178.14 | 0.00 | -3133.00 | -575.38 |
| Debt to Market Cap | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.21 | 0.00 | 0.01 | 0.01 | 0.00 |
| Net Debt to EBITDA | -44.28 | -5.20 | 1.02 | 1.28 | 1.10 |
| Profitability Margins | |||||
| Gross Profit Margin | 89.93% | 88.96% | 87.71% | 82.34% | 61.73% |
| EBIT Margin | 0.33% | 3.15% | -27.85% | -151.86% | -5141.84% |
| EBITDA Margin | 0.49% | 3.26% | -27.60% | -150.49% | -5119.90% |
| Operating Profit Margin | -4.72% | -4.24% | 27.85% | -244.86% | -3816.33% |
| Pretax Profit Margin | 0.32% | 3.12% | -29.54% | -151.93% | -5148.47% |
| Net Profit Margin | -4.22% | -6.23% | -34.41% | -151.97% | -5132.65% |
| Continuous Operations Profit Margin | -1.28% | -0.89% | -31.10% | -151.97% | -5148.47% |
| Net Income Per EBT | -1322.35% | -199.56% | 116.51% | 100.03% | 99.69% |
| EBT Per EBIT | -6.77% | -73.70% | -106.07% | 62.05% | 134.91% |
| Return on Assets (ROA) | -10.68% | -19.81% | -67.72% | -55.75% | -80.00% |
| Return on Equity (ROE) | -20.08% | -35.49% | -114.55% | -60.82% | -111.10% |
| Return on Capital Employed (ROCE) | -13.69% | -17.76% | 86.49% | -100.34% | -83.01% |
| Return on Invested Capital (ROIC) | 54.92% | 5.06% | 86.06% | -100.11% | -82.75% |
| Return on Tangible Assets | -10.68% | -19.81% | -67.72% | -55.75% | -80.00% |
| Earnings Yield | -5.15% | -4.60% | -8.03% | -10.10% | -7.27% |
| Efficiency Ratios | |||||
| Receivables Turnover | 28.19 | 117.75 | 54.85 | 41.27 | 0.00 |
| Payables Turnover | 11.41 | 17.57 | 14.99 | 4.76 | 1.42 |
| Inventory Turnover | 1.23 | 0.98 | 0.96 | 0.40 | 0.15 |
| Fixed Asset Turnover | 309.44 | 260.50 | 100.42 | 26.11 | 3.63 |
| Asset Turnover | 2.53 | 3.18 | 1.97 | 0.37 | 0.02 |
| Working Capital Turnover Ratio | 3.33 | 5.27 | 2.62 | 0.34 | 0.07 |
| Cash Conversion Cycle | 277.61 | 354.85 | 362.09 | 845.44 | 2224.07 |
| Days of Sales Outstanding | 12.95 | 3.10 | 6.65 | 8.84 | 0.00 |
| Days of Inventory Outstanding | 296.66 | 372.52 | 379.78 | 913.31 | 2482.00 |
| Days of Payables Outstanding | 31.99 | 20.78 | 24.35 | 76.71 | 257.93 |
| Operating Cycle | 309.60 | 375.62 | 386.44 | 922.15 | 2482.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.11 | -0.38 | -1.01 | -1.62 | -1.97 |
| Free Cash Flow Per Share | 0.11 | -0.38 | -1.02 | -1.63 | -1.98 |
| Dividend Paid and CapEx Coverage Ratio | 30.94 | -105.27 | -84.87 | -233.35 | -161.68 |
| Capital Expenditure Coverage Ratio | 30.94 | -105.27 | -84.87 | -233.35 | -161.68 |
| Operating Cash Flow Coverage Ratio | 0.53 | -157.90 | -118.30 | -178.44 | -6629.00 |
| Operating Cash Flow to Sales Ratio | 0.02 | -0.05 | -0.29 | -2.37 | -33.82 |
| Free Cash Flow Yield | 2.19% | -4.00% | -6.74% | -15.82% | -4.82% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -19.52 | -22.58 | -12.46 | -9.90 | -13.76 |
| Price-to-Sales (P/S) Ratio | 0.82 | 1.35 | 4.29 | 15.05 | 706.47 |
| Price-to-Book (P/B) Ratio | 3.90 | 7.71 | 14.27 | 6.02 | 15.29 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 45.60 | -25.00 | -14.83 | -6.32 | -20.76 |
| Price-to-Operating Cash Flow Ratio | 44.13 | -25.23 | -15.00 | -6.35 | -20.89 |
| Price-to-Earnings Growth (PEG) Ratio | 0.48 | 0.35 | -0.72 | 0.15 | 0.26 |
| Enterprise Value Multiple | 123.74 | 36.26 | -14.51 | -8.72 | -12.70 |
| Enterprise Value | 16.09M | 34.85M | 54.71M | 33.60M | 127.42M |
| EV to EBITDA | 123.74 | 36.26 | -14.51 | -8.72 | -12.70 |
| EV to Sales | 0.60 | 1.18 | 4.01 | 13.13 | 650.11 |
| EV to Free Cash Flow | 33.58 | -21.86 | -13.85 | -5.51 | -19.10 |
| EV to Operating Cash Flow | 32.50 | -22.07 | -14.01 | -5.54 | -19.22 |
| Tangible Book Value Per Share | 1.84 | 1.67 | 1.14 | 1.67 | 2.68 |
| Shareholders’ Equity Per Share | 1.25 | 1.23 | 1.06 | 1.71 | 2.69 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 5.01 | 1.29 | -0.05 | -0.00 | 0.00 |
| Revenue Per Share | 5.94 | 7.01 | 3.54 | 0.69 | 0.06 |
| Net Income Per Share | -0.25 | -0.44 | -1.22 | -1.04 | -2.99 |
| Tax Burden | -13.22 | -2.00 | 1.17 | 1.00 | 1.00 |
| Interest Burden | 0.97 | 0.99 | 1.06 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.04 | 0.05 | 0.13 | 0.60 | 7.14 |
| SG&A to Revenue | 0.91 | 0.88 | 0.23 | 1.56 | 18.91 |
| Stock-Based Compensation to Revenue | 0.05 | 0.07 | 0.06 | 0.38 | 11.04 |
| Income Quality | -1.45 | 6.03 | 0.83 | 1.56 | 0.66 |
Currency in USD
